Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUSP3 | P51452 | 3/20 | 0.59 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.48 |
| ▸ | RECQL | P46063 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16639743 | 0.82 | DUSP3 (0.56) | DUSP3PTPN7MEN1KMT2APOLB | |
| SCHEMBL16687570 | 0.76 | KDM4E (0.58) | DUSP3PTPN7MEN1KMT2APOLB | |
| SCHEMBL17789560 | 0.76 | ENPP2 (0.60) | DUSP3PTPN7MEN1KMT2APOLB | |
| SCHEMBL15315392 | 0.75 | POLB (0.50) | DUSP3PTPN7MEN1KMT2APOLB | |
| SCHEMBL13479552 | 0.74 | DUSP3 (1.00) | DUSP3PTPN7MEN1KMT2APOLB | |
| SCHEMBL23692463 | 0.73 | MAPT (0.42) | DUSP3MEN1KMT2APOLBTDP1 | |
| SCHEMBL19597040 | 0.72 | MEN1 (0.53) | DUSP3PTPN7MEN1KMT2APOLB | |
| SCHEMBL46557 | 0.72 | MEN1 (0.70) | MEN1KMT2APOLBL3MBTL1DNMT1 | |
| SCHEMBL6742617 | 0.70 | PTPN12 (0.77) | MEN1KMT2APOLBL3MBTL1DNMT1 | |
| SCHEMBL46216 | 0.70 | PTPN12 (0.77) | MEN1KMT2APOLBL3MBTL1DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170121410-A1 | COMPOSITIONS AND METHODS TO TREAT SOLID TUMORS | WAYNE STATE UNIVERSITY (US) | 2017-05-04 | — | — | US | disclosed |
| US-20160151336-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9328105-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9023876-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121410-A1 | COMPOSITIONS AND METHODS TO TREAT SOLID TUMORS | ITGB8, MMP8, FUT8 | DUSP3 4603/4885PTPN7 1934/4885MEN1 3438/4885 |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ITGA2, ITGB2, ITGA2B | DUSP3 3506/4885PTPN7 3222/4885MEN1 2635/4885 |
| US-20160151336-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ITGA2, ITGB2, ITGA2B | DUSP3 3506/4885PTPN7 3222/4885MEN1 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.